Showing 19,241 - 19,260 results of 31,612 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 5 ((wt decrease) OR (nn decrease)) ))', query time: 1.08s Refine Results
  1. 19241

    Determinants of study power. by Leticia M. Nogueira (501430)

    Published 2013
    “…<p><b>A</b>. Study power decreases with increasing sample storage time (▪0 years, ▴ 5 years, •10 years). …”
  2. 19242

    Longitudinal iGlu<sub>u</sub> imaging experiments reveal forskolin effect on hMFB glutamate release. by Marta Orlando (11001599)

    Published 2021
    “…Data are normalized to the first value, 12 min before the forskolin application. Note 50% bleaching and 25% increased pixel noise. (D) Graph shows the cumulative amplitude, active area, and mean and maximal amplitudes of the iGlu<sub>u</sub> fluorescent signal of the hMFB in (A and B). …”
  3. 19243

    Figure 1 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia by Sydney A. Skupa (18597728)

    Published 2025
    “…<p>CLL alters gut bacterial diversity and generates a dysbiotic microbiome compared with WT. <b>A,</b> Study schematic illustrating transgenic Eμ-TCL1 and WT B6 mice were monitored with serial blood and fecal pellet sample collection over 12 months. …”
  4. 19244
  5. 19245
  6. 19246
  7. 19247
  8. 19248
  9. 19249

    Screening TAS2R5 agonists for the receptor downregulation response to long- term agonist exposure. by Donghwa Kim (252081)

    Published 2025
    “…<p>HEK-293T cells stably expressing FLAG-tagged TAS2R5 were exposed in culture for 18 hrs to the indicated agonists at a concentration 10-fold greater than their functional EC<sub>50</sub> values. …”
  10. 19250

    Contribution of anti-MPER antibodies to the plasma's cross-neutralizing activities. by Iliyana Mikell (120166)

    Published 2011
    “…</p>d<p>The neutralizing activities of plasmas collected at the indicated time points following infection were evaluated against the HIV-1 viruses JRFL and TRO.11 in the absence or presence of the MPER peptide (NEQELL<u>ELDKWASLWNWFDITN</u>WLWYIRKKK). The Log10 decrease in IC50 neutralization titers in the presence of the MPER peptide is indicated.…”
  11. 19251
  12. 19252
  13. 19253

    Cytotoxicity profiles of multi-walled carbon nanotubes with different physico-chemical properties by Katsuhide Fujita (2902233)

    Published 2020
    “…Rigid, needle-shaped MWCNTs with a large diameter (>50 µm) penetrated the cytoplasm and decreased cell survival without generating intracellular reactive oxygen species (ROS), significantly up-regulated many genes involved in inflammatory responses, response to oxidative stress and apoptosis, and extracellular matrix degradation. …”
  14. 19254

    Time Since Deposition Signatures for the Analysis of Canine Body Fluid by Alysia Townsley (20673209)

    Published 2025
    “…<p dir="ltr">Although dogfighting is a felony in all 50 states, it has grown into a substantial enterprise that is often tied to other organized crime activities including gambling, narcotics, and weapons trafficking. …”
  15. 19255

    Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study by Daiane Dias Ferreira (6044783)

    Published 2018
    “…Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. …”
  16. 19256
  17. 19257
  18. 19258

    Exploring <i>in vitro</i> anticancer potential of <i>Ferula gummosa</i> gum on PC-3 cells: insights from cellular and molecular studies by Negar Abdollahzadeh (20507068)

    Published 2025
    “…Alongside this, we observed a decrease in intracellular ROS levels and a weakening of the mitochondrial membrane potential. …”
  19. 19259
  20. 19260

    Modeling of <i>In-Utero</i> and <i>Intra-Partum</i> Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV by Patumrat Sripan (741310)

    Published 2015
    “…</p><p>Trial Registration</p><p>This analysis is based on secondary data obtained from three clinical trials. ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT00386230" target="_blank">NCT00386230</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT00398684" target="_blank">NCT00398684</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT00409591" target="_blank">NCT00409591</a>.…”